Literature DB >> 15950987

Differential functional effects of two 5-HT4 receptor isoforms in adult cardiomyocytes.

Liliana Castro1, Jeanne Mialet-Perez, Aurélie Guillemeau, Francesca Stillitano, Oliver Zolk, Thomas Eschenhagen, Frank Lezoualc'h, Pascal Bochet, Rodolphe Fischmeister.   

Abstract

Serotonin 5-HT4 receptors are present in human atrial myocytes and have been proposed to contribute to the generation of atrial fibrillation. However, 5-HT4 receptors have so far been only found in human and pig atria and are absent from the heart of small laboratory animals, such as rat, guinea pig, rabbit and frog, which limits the experimental settings for studying their functional properties. In this study, we developed an adenovirus expression system to examine the properties of two human 5-HT4 receptor splice variants, h5-HT4(b) and h5-HT4(d), expressed in adult cardiomyocytes devoid of native 5-HT4 receptors. When expressed in the HL-1 murine cell line of atrial origin, both receptors caused specific binding of the 5-HT4 selective antagonist GR113808 and activated adenylyl cyclase in the presence of serotonin (5-HT, 1 microM). When expressed in freshly isolated adult rat ventricular cardiomyocytes, a stimulation of the L-type Ca2+ current (ICa,L) by 5-HT (100 nM) was revealed. Both effects were blocked by GR113808. In HL-1 cells, the h5-HT4(d) receptor was found to be more efficiently coupled to adenylyl cyclase than the h5-HT4(b). Pertussis toxin treatment (250 ng/ml for 5 h) potentiated the stimulatory effect of 5-HT on ICa,L in rat myocytes expressing the h5-HT4(b) but not the h5-HT4(d) receptor, indicating a likely coupling of the (b) isoform to both Gs and Gi/o proteins. Adenoviral expression of h5-HT4 receptor isoforms in adult cardiac myocytes provides a valuable means for the exploration of the receptor signaling cascades in normal and pathological situations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15950987     DOI: 10.1016/j.yjmcc.2005.04.009

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  7 in total

1.  The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity.

Authors:  J A M Smith; D T Beattie; D Marquess; J P Shaw; R G Vickery; P P A Humphrey
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-04-16       Impact factor: 3.000

2.  Role of cAMP/PKA pathway and T-type calcium channels in the mechanism of action of serotonin in human adrenocortical cells.

Authors:  Estelle Louiset; Céline Duparc; Sébastien Lenglet; Celso E Gomez-Sanchez; Hervé Lefebvre
Journal:  Mol Cell Endocrinol       Date:  2016-10-12       Impact factor: 4.102

3.  Porcine left atrial and sinoatrial 5-HT(4) receptor-induced responses: fading of the response and influence of development.

Authors:  Joris H De Maeyer; Roel Straetemans; Jan A J Schuurkes; Romain A Lefebvre
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

Review 4.  Serotonin pharmacology in the gastrointestinal tract: a review.

Authors:  D T Beattie; J A M Smith
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-04-09       Impact factor: 3.000

5.  Electrophysiological and arrhythmogenic effects of 5-hydroxytryptamine on human atrial cells are reduced in atrial fibrillation.

Authors:  Davide Pau; Antony J Workman; Kathleen A Kane; Andrew C Rankin
Journal:  J Mol Cell Cardiol       Date:  2006-09-20       Impact factor: 5.000

6.  Human 5-HT(4) and 5-HT(7) receptor splice variants: are they important?

Authors:  Ian M Coupar; Paul V Desmond; Helen R Irving
Journal:  Curr Neuropharmacol       Date:  2007-12       Impact factor: 7.363

7.  A preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology.

Authors:  Anita Arya; John Silberbauer; Sam L Teichman; Peter Milner; Neil Sulke; A John Camm
Journal:  Europace       Date:  2009-01-26       Impact factor: 5.214

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.